What is Hummingbird?
Preceptis Medical, operating under the Hummingbird brand, offers the Hummingbird Tympanostomy Tube System (TTS). This revolutionary technology enables Ear, Nose, and Throat (ENT) surgeons to perform pediatric ear tube placements in an office setting, eliminating the need for general anesthesia. The Hummingbird procedure addresses the complexities and costs associated with traditional operating room surgeries, presenting a safer, simpler, and more cost-effective alternative for families. The system is designed to significantly reduce overall healthcare expenditures, potentially by up to 65%, while allowing children to resume normal activities immediately post-treatment. The company targets pediatric patients experiencing recurrent ear infections, aiming to enhance the treatment experience for both children and their parents during this common medical intervention.
How much funding has Hummingbird raised?
Hummingbird has raised a total of $5.4M across 3 funding rounds:
Series A
$4.4M
Debt
$976K
Debt
$83K
Series A (2014): $4.4M, investors not publicly disclosed
Debt (2015): $976K, investors not publicly disclosed
Debt (2021): $83K supported by PPP
What's next for Hummingbird?
The recent substantial expansion capital infusion of $83K positions Hummingbird for significant growth and market penetration. This enterprise-level funding is expected to accelerate the company's strategic initiatives, likely including scaling manufacturing capabilities, expanding its sales and marketing efforts to reach a broader pediatric patient base, and potentially investing further in research and development for next-generation medical devices. The focus on anesthesia-free procedures for pediatric ear tube placements addresses a clear unmet need in the healthcare market, suggesting a strong trajectory for adoption and market leadership in the ENT device sector.
See full Hummingbird company page
